UNSPSC 51371801: Promedol or trimeperidine

This classification denotes an opioid receptor agonist with the molecular formula C17H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1M2IB31DTS, chemically known as 1,2,5-trimethyl-4-phenyl-4-propionyloxypiperidine but generally known as promedol, which bears US NIH Compound Identifier 6148. European Medicines Agency schedules Trimeperidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11303MIG. The term PROMEDOL is an International Non-Proprietary Name.

Promedol or trimeperidine bears US NLM identifiers UMLS ID C0041029 and NCI Concept Code C76848. SMILES: CCC(=O)OC1(C[C@@H](N(C[C@H]1C)C)C)C2=CC=CC=C2.

UNSPSC 51371801 Promedol or trimeperidine is a Commodity code that in recent state and local solicitations covers pharmaceutical supply and procurement — though the recent opportunities show limited direct activity under this specific opioid code and instead reflect broader pharmaceutical purchasing by state health agencies and county health departments. State and local governments procure pharmaceuticals, including controlled substances, naloxone, and over-the-counter products through competitive bidding and cooperative purchasing arrangements. Soliciting bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, which also serves Oregon). These jurisdictions purchase through authorized pharmaceutical wholesalers, require vendors to hold current Good Manufacturing Practices certification and Drug Supply Chain Security Act compliance, and structure contracts with administrative fees, performance penalties, and insurance requirements including commercial general liability and professional liability coverage.

Recent activity centers in Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: the due date appears inconsistent with the posted date and likely reflects a legacy or corrected solicitation record). Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, evaluating vendors on pricing competitiveness (75 percent weight), administrative compliance, EDI capability, and fixed pricing. No awards under this specific code are named in the recent record.